JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Search

Danaher Corp

Geschlossen

BrancheGesundheitswesen

174.62 0.32

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

173.22

Max

176.42

Schlüsselkennzahlen

By Trading Economics

Einkommen

-168M

1B

Verkäufe

-887M

6B

KGV

Branchendurchschnitt

34.936

67.147

EPS

2.06

Dividendenrendite

0.77

Gewinnspanne

17.291

Angestellte

58,000

EBITDA

-514M

1.5B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+34.3% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.77%

2.36%

Nächstes Ergebnis

21. Juli 2026

Nächste Dividendenausschüttung

24. Juli 2026

Nächstes Ex-Dividendendatum

26. Juni 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-11B

128B

Vorheriger Eröffnungskurs

174.3

Vorheriger Schlusskurs

174.62

Nachrichtenstimmung

By Acuity

23%

77%

76 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Danaher Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Apr. 2026, 11:36 UTC

Ergebnisse

Danaher Lifts Full-Year Forecast on Biotech, Life Sciences Gains -- Update

21. Apr. 2026, 11:00 UTC

Ergebnisse

Danaher Raises Adjusted Earnings Guidance, 1Q Revenue, Profit Rise

21. Apr. 2026, 10:06 UTC

Ergebnisse

Danaher 1Q Adjsuted Core Revenue Rose 0.5% >DHR

21. Apr. 2026, 10:05 UTC

Ergebnisse

Danaher Sees 2Q Adjsuted Core Revenue Up Low-Single Digits >DHR

21. Apr. 2026, 10:05 UTC

Ergebnisse

Danaher Still Sees 2026 Adjsuted Core Revenue Up 3%-6% >DHR

21. Apr. 2026, 10:05 UTC

Ergebnisse

Danaher Had Seen 2026 Adjusted EPS $8.35-$8.50 >DHR

21. Apr. 2026, 10:04 UTC

Ergebnisse

Danaher Raises 2026 View To Adj EPS $8.35-Adj EPS $8.55 >DHR

21. Apr. 2026, 10:04 UTC

Ergebnisse

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

21. Apr. 2026, 10:00 UTC

Ergebnisse

Danaher 1Q Cont Ops EPS $1.45 >DHR

21. Apr. 2026, 10:00 UTC

Ergebnisse

Danaher 1Q Adj EPS $2.06 >DHR

21. Apr. 2026, 10:00 UTC

Ergebnisse

Danaher 1Q Sales $5.95B >DHR

21. Apr. 2026, 10:00 UTC

Ergebnisse

Danaher 1Q EPS $1.45 >DHR

21. Apr. 2026, 10:00 UTC

Ergebnisse

Danaher 1Q Net $1.03B >DHR

17. Apr. 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17. Apr. 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17. Feb. 2026, 20:06 UTC

Akquisitionen, Fusionen, Übernahmen

This Medical-Devices Stock Is Soaring. Danaher Is Buying the Company. -- Barrons.com

17. Feb. 2026, 15:14 UTC

Akquisitionen, Fusionen, Übernahmen

Masimo Stock on Pace for Record Gains After Danaher Strikes Deal -- WSJ

17. Feb. 2026, 14:39 UTC

Akquisitionen, Fusionen, Übernahmen

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17. Feb. 2026, 13:30 UTC

Akquisitionen, Fusionen, Übernahmen

This Medical-Devices Stock Is Soaring. It's Being Bought by Danaher. -- Barrons.com

17. Feb. 2026, 13:15 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher Strikes $10 Billion Deal for Masimo -- Update

17. Feb. 2026, 13:03 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher To Fund Masimo Acquisition With Cash on Hand, Debt Financing >DHR

17. Feb. 2026, 13:03 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher Sees More Than $125M Annual Cost Synergies, More Than $50M Annual Revenue Synergies by Fifth Full Year >DHR MASI

17. Feb. 2026, 13:02 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher Sees Masimo Deal Adding About 70c to Adjusted EPS in Fifth Full Year >DHR MASI

17. Feb. 2026, 13:02 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher Sees Masimo Deal Adding 15c-20c to Adjusted EPS in First Full Year >DHR MASI

17. Feb. 2026, 13:02 UTC

Akquisitionen, Fusionen, Übernahmen

Masimo To Be Acquired By Danaher For $180.00 Per Share >MASI DHR

17. Feb. 2026, 13:01 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher to Buy Masimo for Total Enterprise Value of About $9.9 Billion >DHR MASI

17. Feb. 2026, 13:00 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher to Buy Masimo for $180/Share >DHR MASI

17. Feb. 2026, 13:00 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher To Acquire Masimo Corporation >DHR MASI

17. Feb. 2026, 11:09 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher Strikes $10 Billion Deal for Masimo -- WSJ

17. Feb. 2026, 11:09 UTC

Akquisitionen, Fusionen, Übernahmen

Danaher Acquisition of Masimo Set to Be Announced Tuesday, Sources Say -- WSJ

Peer-Vergleich

Kursveränderung

Danaher Corp Prognose

Kursziel

By TipRanks

34.3% Vorteil

12-Monats-Prognose

Durchschnitt 233.74 USD  34.3%

Hoch 270 USD

Tief 184.04 USD

Basierend auf 16 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Danaher Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

16 ratings

14

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

189.8851 / 196.5Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Neutral Evidence

Stimmung

By Acuity

76 / 347 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat